Catalent wins bidding war to take on UK's VMIC
When a source from the UK government talked to the Financial Times back in December about the potential sale of a ready-made vaccine manufacturing site, one thing was made clear: Stakeholders wanted to sell it to “someone who knows how to run it.” Four months later, it looks like Catalent is that someone.
A biologics manufacturing and development center already in the midst of construction in the UK now belongs to Catalent, and will get an additional $160 million investment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.